Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric...

Area of Science:

• Pediatric Infectious Diseases
• Immunology
• Virology

Background:

• Highly active antiretroviral therapy (HAART) is crucial for managing HIV-1 infection in children.
• Understanding factors influencing HAART response is essential for optimizing treatment outcomes.
• Age and immunological status (CD4%) are key considerations in pediatric HIV management.

Purpose of the Study:

• To evaluate how age, CD4 percentage (CD4%), and plasma HIV-1 RNA levels affect HAART response in previously untreated children.
• To identify specific patient characteristics that predict immunological and virological responses to HAART.

Main Methods:

• A cohort study design was employed to analyze treatment responses.
• Logistic and Cox regression models were used to examine associations between age at HAART initiation, CD4%, and HIV-1 RNA response.
• Analyses were adjusted for sex, route of infection, and pre-HAART values.

Main Results:

• Younger children and those with lower baseline CD4% showed greater CD4% increases at 6 months.
• Older children were more likely to achieve HIV-1 RNA suppression (<400 copies/ml) at 6 months.
• Immunological response (CD4% increase) was faster in younger children, while virological response (HIV-1 RNA decrease) was slower, potentially increasing resistance risk.

Conclusions:

• Children achieve immunological responses to HAART regardless of baseline viral load or clinical status.
• Younger children and those with lower CD4% exhibit superior immunological recovery but poorer virological response.
• Age-related differences in HAART response necessitate tailored treatment strategies to mitigate resistance risk.